References
- Bayes-Genis A, Januzzi JL, Gaggin HK, et al. (2015). ST2 pathogenetic profile in ambulatory heart failure patients. J Card Fail 21:355–61
- Boisot S, Beede J, Isakson S, et al. (2008). Serial sampling of St2 predicts 90-day mortality following destabilized heart failure. J Card Fail 14:732–8
- Breidthardt T, Balmelli C, Twerenbold R, et al. (2013). Heart failure therapy-induced early changes may offer long-term therapy guidance. J Card Fail 19:821–8
- Bueno H, Ross JS, Chen J, et al. (2010). Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993–2006. JAMA 303:2141–7
- Januzzi JL Jr, Peacock WF, Maisel AS, et al. (2007). Measurement of the interleukin family member ST2 in patients with acute dyspnea. JACC 50:607–13
- Manzano-Fernández S, Januzzi JL, Pastor-Pérez FJ, et al. (2012). Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure. Cardiology 122:158–66
- Mebazza A, Di Somma S, Maisel A, Bayes-Genis A. (2015). ST2 and multimarker testing in acute decompensated heart failure. Am J Cardiol 115:38B–43
- Mozaffarian D, Benjamin EJ, Go AS, et al. (2015). Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 131:e29–322
- Mueller T, Jaffe A. (2015). Soluble ST2-analytical considerations. International ST2 Consensus Panel. Am J Cardiol 115:8B–21
- Rehman S, Mueller T, Januzzi J. (2008). Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 52:1458–65
- Yancy CW, Jessup M, Bozkurt B, et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013). 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 128:e240–327